Nothing Special   »   [go: up one dir, main page]
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE

Nature Immunology volume 10, pages 958–964 (2009)Cite this article

A Corrigendum to this article was published on 01 January 2010

This article has been updated

Abstract

Multiple sclerosis is an inflammatory disease of the central nervous system that begins as a relapsing-remitting disease (RRMS) and is followed by a progressive phase (SPMS). The progressive phase causes the greatest disability and has no effective therapy, but the processes that drive SPMS are mostly unknown. Here we found higher serum concentrations of 15α-hydroxicholestene (15-HC) in patients with SPMS and in mice with secondary progressive experimental autoimmune encephalomyelitis (EAE) but not in patients with RRMS. In mice, 15-HC activated microglia, macrophages and astrocytes through a pathway involving Toll-like receptor 2 (TLR2) and poly(ADP-ribose) polymerase 1 (PARP-1). PARP-1 activity was higher in monocytes of patients with SPMS, and PARP-1 inhibition suppressed the progression of EAE. Thus, the TLR2–PARP-1 pathway is a potential new therapeutic target in SPMS.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Higher 15-HC serum concentrations in human SPMS and secondary progressive EAE.
Figure 2: Inhibition of PARP-1 suppresses axonal loss and progressive disability in secondary progressive EAE.
Figure 3: Activation of PARP-1 during human SPMS and secondary progressive EAE.
Figure 4: Activation of microglia, macrophages and astrocytes by 5-HC via PARP-1.
Figure 5: Signaling events mediating the activation of PARP-1 by 15-HC.
Figure 6: Activation of PARP-1 by 15-HC is mediated by TLR2.

Similar content being viewed by others

Change history

  • 18 September 2009

    NOTE: In the version of this article initially published, two citations were not included. These citations, together with text describing their content, have been added to page 958, column 2, as follows: “As neuronal loss is thought to contribute to the pathogenesis of progressive multiple sclerosis5, and as PARP-1 inhibitors suppress the incidence and severity of experimental autoimmune encephalomyelitis (EAE)36,37, we investigated the function of 15-oxysterols in multiple sclerosis and EAE.” The added references are as follows: 36. Scott, G.S. et al. Role of poly(ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis. J. Neuroimmunol. 117, 78–86 (2001). 37. Scott, G.S. et al. The therapeutic effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J. Pharmacol. Exp. Ther. 310, 1053–1061 (2004). The error has been corrected in the HTML and PDF versions of the article.

References

  1. McFarland, H.F. & Martin, R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8, 913–919 (2007).

    Article  CAS  Google Scholar 

  2. Compston, A. & Coles, A. Multiple sclerosis. Lancet 372, 1502–1517 (2008).

    Article  CAS  Google Scholar 

  3. Rovaris, M. et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 5, 343–354 (2006).

    Article  Google Scholar 

  4. Lopez-Diego, R.S. & Weiner, H.L. Novel therapeutic strategies for multiple sclerosis—a multifaceted adversary. Nat. Rev. Drug Discov. 7, 909–925 (2008).

    Article  CAS  Google Scholar 

  5. Trapp, B.D. & Nave, K.A. Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci. 31, 247–269 (2008).

    Article  CAS  Google Scholar 

  6. Trapp, B.D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278–285 (1998).

    Article  CAS  Google Scholar 

  7. Balashov, K.E., Comabella, M., Ohashi, T., Khoury, S.J. & Weiner, H.L. Defective regulation of IFNγ and IL-12 by endogenous IL-10 in progressive MS. Neurology 55, 192–198 (2000).

    Article  CAS  Google Scholar 

  8. Balashov, K.E., Smith, D.R., Khoury, S.J., Hafler, D.A. & Weiner, H.L. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc. Natl. Acad. Sci. USA 94, 599–603 (1997).

    Article  CAS  Google Scholar 

  9. Comabella, M. et al. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J. Clin. Invest. 102, 671–678 (1998).

    Article  CAS  Google Scholar 

  10. Karni, A., Koldzic, D.N., Bharanidharan, P., Khoury, S.J. & Weiner, H.L. IL-18 is linked to raised IFN-γ in multiple sclerosis and is induced by activated CD4+ T cells via CD40–CD40 ligand interactions. J. Neuroimmunol. 125, 134–140 (2002).

    Article  CAS  Google Scholar 

  11. Karni, A. et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. 177, 4196–4202 (2006).

    Article  CAS  Google Scholar 

  12. Weiner, H.L. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J. Neurol. 255, 3–11 (2008).

    Article  CAS  Google Scholar 

  13. Quintana, F.J. et al. Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes. Proc. Natl. Acad. Sci. USA 101, 14615–14621 (2004).

    Article  CAS  Google Scholar 

  14. Robinson, W.H. et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat. Biotechnol. 21, 1033–1039 (2003).

    Article  CAS  Google Scholar 

  15. Quintana, F.J. et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc. Natl. Acad. Sci. USA 105, 18889–18894 (2008).

    Article  CAS  Google Scholar 

  16. Diestel, A. et al. Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J. Exp. Med. 198, 1729–1740 (2003).

    Article  CAS  Google Scholar 

  17. Basso, A.S. et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J. Clin. Invest. 118, 1532–1543 (2008).

    Article  CAS  Google Scholar 

  18. Suto, M.J., Turner, W.R., Arundel-Suto, C.M., Werbel, L.M. & Sebolt-Leopold, J.S. Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anticancer Drug Des. 6, 107–117 (1991).

    CAS  PubMed  Google Scholar 

  19. Jack, C., Ruffini, F., Bar-Or, A. & Antel, J.P. Microglia and multiple sclerosis. J. Neurosci. Res. 81, 363–373 (2005).

    Article  CAS  Google Scholar 

  20. Nair, A., Frederick, T.J. & Miller, S.D. Astrocytes in multiple sclerosis: a product of their environment. Cell. Mol. Life Sci. 65, 2702–2720 (2008).

    Article  CAS  Google Scholar 

  21. Smith, K.J. & Lassmann, H. The role of nitric oxide in multiple sclerosis. Lancet Neurol. 1, 232–241 (2002).

    Article  CAS  Google Scholar 

  22. Charo, I.F. & Ransohoff, R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610–621 (2006).

    Article  CAS  Google Scholar 

  23. Kanter, J.L. et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 12, 138–143 (2006).

    Article  CAS  Google Scholar 

  24. Chan, S.M., Ermann, J., Su, L., Fathman, C.G. & Utz, P.J. Protein microarrays for multiplex analysis of signal transduction pathways. Nat. Med. 10, 1390–1396 (2004).

    Article  CAS  Google Scholar 

  25. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783–801 (2006).

    Article  CAS  Google Scholar 

  26. Cohen-Armon, M. et al. DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol. Cell 25, 297–308 (2007).

    Article  CAS  Google Scholar 

  27. Leoni, V., Lutjohann, D. & Masterman, T. Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J. Lipid Res. 46, 191–195 (2005).

    Article  CAS  Google Scholar 

  28. Kutzelnigg, A. et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705–2712 (2005).

    Article  Google Scholar 

  29. Bongarzone, E.R., Pasquini, J.M. & Soto, E.F. Oxidative damage to proteins and lipids of CNS myelin produced by in vitro generated reactive oxygen species. J. Neurosci. Res. 41, 213–221 (1995).

    Article  CAS  Google Scholar 

  30. Luo, J. et al. Glia-dependent TGF-β signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. J. Clin. Invest. 117, 3306–3315 (2007).

    Article  CAS  Google Scholar 

  31. Pitt, D., Werner, P. & Raine, C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6, 67–70 (2000).

    Article  CAS  Google Scholar 

  32. Smith, T., Groom, A., Zhu, B. & Turski, L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6, 62–66 (2000).

    Article  CAS  Google Scholar 

  33. Quintana, F.J. et al. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature 453, 65–71 (2008).

    Article  CAS  Google Scholar 

  34. Meng, G. et al. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J. Clin. Invest. 113, 1473–1481 (2004).

    Article  CAS  Google Scholar 

  35. Qi, H.Y. & Shelhamer, J.H. Toll-like receptor 4 signaling regulates cytosolic phospholipase A2 activation and lipid generation in lipopolysaccharide-stimulated macrophages. J. Biol. Chem. 280, 38969–38975 (2005).

    Article  CAS  Google Scholar 

  36. Scott, G.S. et al. Role of poly(ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis. J. Neuroimmunol. 117, 78–86 (2001).

    Article  CAS  Google Scholar 

  37. Scott, G.S et al. The therapeutic effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J. Pharmacol. Exp. Ther. 310, 1053–1061 (2004).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank A.S. Basso (Universidade Federal de São Paulo) for discussions, and M. Oukka (Harvard Medical School) for TLR2-deficient mice. Supported by the US National Institutes of Health (AI435801 and NS38037), the US National Multiple Sclerosis Society (PP1289 to H.L.W.) and the Human Frontiers of Science Program Organization (F.J.Q.).

Author information

Author notes

  1. Mauricio F Farez and Francisco J Quintana: These authors contributed equally to this work.

Authors and Affiliations

  1. Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

    Mauricio F Farez, Francisco J Quintana, Roopali Gandhi & Howard L Weiner

  2. Molecular Biology Service, University of Sevilla, Sevilla, Spain

    Guillermo Izquierdo & Miguel Lucas

  3. Multiple Sclerosis Unit, University of Sevilla, Sevilla, Spain

    Guillermo Izquierdo

Authors
  1. Mauricio F Farez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francisco J Quintana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roopali Gandhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guillermo Izquierdo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Miguel Lucas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Howard L Weiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.F.F and F.J.Q. did experiments and analyzed data; R.G. provided purified human monocytes; G.I and M.L. contributed samples; and M.F.F., F.J.Q. and H.L.W. wrote the manuscript.

Corresponding authors

Correspondence to Francisco J Quintana or Howard L Weiner.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–5 and Supplementary Tables 1–6 (PDF 955 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Farez, M., Quintana, F., Gandhi, R. et al. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol 10, 958–964 (2009). https://doi.org/10.1038/ni.1775

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ni.1775

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing